Date: 2015-11-19
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the 57th American Society of Hematology (ASH) Annual Meeting in Orlando
Company: Hybrigenics (France)
Product: inecalcitol
Action
mechanism: vitamin D analog
Disease: chronic myeloid leukemia (CML)
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On November 19, 2015, Hybrigenics announced new in vitro results of inecalcitol on human chronic myeloid leukemia (CML) progenitors and stem cells in culture which will be presented at the 57th Annual Meeting of the American Society of Hematology (ASH) in Orlando, United States. A collaboration between Hybrigenics, hemato-oncologists from the University Hospitals of Caen, Nancy and Paris-Sud and researchers from Inserm Units in Villejuif and Paris, led by Prof. A. Turhan, Head of Hematology and Inserm U935, Paris-Sud University, has confirmed the inhibitory synergy on leukemic stem cells isolated from CML patients between inecalcitol and either imatinib (Gleevec®, Novartis), dasatinib (Sprycel®, BMS) or nilotinib (Tasigna®, Novartis), three different Bcr-Abl tyrosine kinase inhibitors widely used to treat CML. By contrast, the combination of inecalcitol and any of these three Bcr-Abl inhibitors had no effect on normal myeloid progenitor cells. Inecalcitol has been tested on in vitro cultures of CML stem cells isolated from a total of 18 different patients and shown to exert growth inhibition by itself, without any Bcr-Abl inhibitor, on CML stem cells from 15 out of these 18 patients. In addition, under the in vitro effect of inecalcitol alone, a panel of genes characteristic of differentiation of CML stem cells into macrophages has been identified, which could potentially be used as biomarkers predictive of clinical response to inecalcitol (Inecalcitol, a Novel Adjuvant Therapy Inhibiting Chronic Myeloid Leukemia (CML) Stem Cells, Activates a Macrophage Differentiation Pathway in Leukemic Progenitors)
